[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN110105230B - 一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法 - Google Patents

一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法 Download PDF

Info

Publication number
CN110105230B
CN110105230B CN201910439860.8A CN201910439860A CN110105230B CN 110105230 B CN110105230 B CN 110105230B CN 201910439860 A CN201910439860 A CN 201910439860A CN 110105230 B CN110105230 B CN 110105230B
Authority
CN
China
Prior art keywords
palladium
amine compound
formula
synthesizing
aromatic amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910439860.8A
Other languages
English (en)
Other versions
CN110105230A (zh
Inventor
陈万芝
陈威
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CN201910439860.8A priority Critical patent/CN110105230B/zh
Publication of CN110105230A publication Critical patent/CN110105230A/zh
Application granted granted Critical
Publication of CN110105230B publication Critical patent/CN110105230B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/55—Diphenylamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C07C211/58—Naphthylamines; N-substituted derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

本发明公开了一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺的方法，包括：在有机溶剂中，以钯/咪唑盐为催化剂，将硝基芳烃和胺类化合物在碱的作用下进行偶联反应，经过后处理得到芳香胺化合物。本发明方法配体合成简单，易于保存，价格便宜且配体的用量较低，产物收率高，底物适用性好，可适用于二芳基胺、N‑烷基芳胺的制备。本发明方法可用于合成一系列芳香胺化合物，该类化合物在农药、医药、材料等领域均有广泛的应用价值。

Description

一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合 物的方法
技术领域
本发明涉及有机合成领域，具体涉及钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法。
背景技术
芳香胺化合物是合成各种医药、农药、染料、聚合物以及精细化学品的重要中间体(Ruiz-Castillo,P.；Buchwald,S.L.Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions，Chemical Reviews，2016,116(19),12564–12649)，而钯催化的Buchwald-Hartwig偶联反应是一种高效构建C-N键的方法。
Buchwald-Hartwig偶联反应一般由卤代芳烃作为亲电试剂，但是为了减少卤代芳烃所产生的含卤废弃物污染，化学家发展了其他拟卤芳烃如醚，酯等为亲电试剂的偶联反应。其中，硝基芳烃是基础化工原料，来源广泛，是理想的亲电偶联试剂。
硝基芳烃的Buchwald-Hartwig偶联反应已有文献报道(Inoue,F.；Kashihara,M.；Yadav,M.R.；Nakao,Y.Buchwald-Hartwig Amination of Nitroarenes，AngewandteChemie International Edition，2017,56(43),13307–13309)，该反应使用的是膦配体Brettphos(2-二环己基膦基-3,6-二甲氧基-2’,4’,6’-三异丙基联苯)。但是，上述膦配体的制备条件苛刻、对空气敏感、价格昂贵，且其催化剂的效率不高，导致该反应中的催化剂用量较大，底物范围小，因此开发新配体来实现硝基苯的Buchwald-Hartwig偶联反应有重要的意义。
N-杂环卡宾是一类强σ-给电子体，其给电子能力可以与膦配体相媲美，通过增大N-杂环卡宾配体的位阻所设计出来的N-杂环卡宾配体是膦配体强有力的竞争者，目前在许多偶联反应中，都出现了效果拔群，能够替代磷配体的N-杂环卡宾配体(Valente,C.；
Figure BDA0002071715990000022
S.；Hoi,K.H.；Mallik,D.；Sayah,M.；Organ,M.G.The Development of BulkyPalladium NHC Complexes for the Most-Challenging Cross-Coupling Reactions，Angew.Chem.Int.Ed.2012,51(14),3314–3332)。
发明内容
本发明的目的在于提供了一种钯/咪唑盐催化硝基芳烃和胺类化合物偶联合成芳香族化合物的方法，该反应操作简单、收率高、配体用量较低、底物适用性好，适合大规模的推广应用。
为了实现上述发明目的，本发明的技术方案如下：
一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法，包括：在有机溶剂中，以钯/咪唑盐为催化剂，将硝基芳烃和胺类化合物在碱的作用下进行偶联反应，经后处理得到芳香族化合物；
所述的硝基芳烃的结构如下式(I)所示：
Ar-NO2 (I)
所述的胺类化合物的结构如下式(II)所示：
Figure BDA0002071715990000021
式(I)中，Ar为芳基或杂芳基；式(II)中，R1为氢或烷基，R2为烷基、芳基或杂芳基。
作为优选，式(I)中，Ar为苯基、取代苯基或含氮杂芳基；式(II)中，R1为氢或烷基，R2为烷基、苯基、取代苯基或含氮杂环。
上述合成方法的反应方程式如下：
Figure BDA0002071715990000031
本发明中的钯/咪唑盐在碱作用下原位生成N-杂环卡宾零价钯配合物，然后对硝基芳烃进行氧化加成，在碱作用下与胺类化合物进行转金属化，还原消除得到芳香胺化合物，同时再生得到N-杂环卡宾零价钯配合物，完成催化循环，不仅减少了配体的用量，还提高了产物的收率。
所述的咪唑盐的结构如下式(III)所示：
Figure BDA0002071715990000032
式(III)中，R1、R2、R3独立的选自氢、卤素、烷基或烷氧基，Y-为Cl-、Br-、I-、PF6 -或BF4 -。
作为优选，上述咪唑盐的结构如下式中的L1～L9所示：
Figure BDA0002071715990000033
进一步优选，所述的咪唑盐为L1～L5，这是由于优选的配体会使产物收率更高。
所述的钯为乙酰丙酮钯(II)、醋酸钯(II)、氯化钯(II)、双(乙腈)氯化钯(II)、双(三苯基膦)氯化钯(II)、三氟乙酸钯(II)、三(二亚苄基丙酮)二钯或烯丙基氯化钯(II)二聚体中的任意一种。
作为优选，所述的钯为乙酰丙酮钯(II)、醋酸钯(II)、氯化钯(II)、双(乙腈)氯化钯(II)、三氟乙酸钯(II)或烯丙基氯化钯(II)二聚体中的任意一种，优选的钯盐制得的产物收率更高。
所述的溶剂为二氧六环、甲苯、四氢呋喃、N,N-二甲基甲酰胺、乙腈、甲基叔丁基醚、正庚烷、异丙醇或乙二醇二甲醚中的任意一种。
作为优选，所述的有机溶剂为二氧六环、甲苯或正己烷，优选的有机溶剂得到的产物收率更高。
以硝基芳烃的摩尔量计，所述有机溶剂的用量为1～10L/mol，优选为4～6L/mol。
所述的碱为磷酸三钾三水合物、无水磷酸钾、碳酸钾、氟化铯、碳酸铯、乙酸钾、磷酸氢二钾、氢氧化钾、三乙胺或1,8-二氮杂二环十一碳-7-烯中的任意一种。
作为优选，所述的碱为磷酸三钾三水合物、无水磷酸钾、氟化铯或碳酸铯中的任意一种。
所述的偶联反应的温度为100～160℃，反应时间为12～48h。
所述的钯、咪唑盐和硝基芳烃的摩尔比为1：(1～4)：(5～100)，优选为1：(1～2)：(10～100)。
所述的硝基芳烃、硼酸化合物和碱的摩尔比为1：(1～3)：(1～5)，优选为1：(1～2)：(1.5～3)。
所述的后处理包括：先利用硅藻土除去不溶物并旋干溶剂，再用硅胶柱色谱进行分离，得到产物。
与现有技术相比，本发明具有以下有益效果：本发明首次将咪唑盐作为N-杂环卡宾前体与钯原位结合后催化硝基芳烃与胺类化合物的Buchwald-Hartwig偶联反应，该反应操作简单，收率高，所用的配体合成简单、易于保存、价格便宜且配体的用量较低，底物适用性好，可用于二芳基胺、N-烷基芳胺的制备。本发明方法可用于合成一系列芳香胺化合物，该类化合物在农药、医药、材料等领域均有广泛的应用价值。
具体实施方式
通过下述实施例将有助于理解本发明，但本发明的内容并不仅限于此。下列实施例中所述的咪唑盐L1～L5的反应方程式如下所示，式(L)中，L1：R1＝R2＝R3＝Me；L2：R1＝R2＝iPr，R3＝H；L3：R1＝R2＝Et，R3＝Me；L4：R1＝R2＝Et，R3＝H；L5：R1＝R2＝Me，R3＝H。
Figure BDA0002071715990000051
具体合成步骤为：
(1)在史莱克管中依次加入A(1mmol,309mg)和B(1.2mmol)。在N2氛围下三抽三通，然后加入10mL甲醇和10μL甲酸(≥88％)，在60℃下反应24h。冷却至室温，反应液抽滤得淡黄固体，用甲醇(3×5mL)洗涤，真空干燥得C；
(2)将C(0.2mmol)，多聚甲醛(0.2mmol,5.9mg)，干燥甲苯(1.5mL)和三甲基氯硅烷TMSCl(0.4mmol,50μL)依次加入到封管中。室温下搅拌24h，反应液旋干后，用乙醚(3×1.5mL)，正己烷(3×1.5mL)洗涤，最后真空干燥得咪唑盐L。
实施例1
Figure BDA0002071715990000061
在氮气氛围中，往干燥的封管中加入92mg的上述硝基芳烃，96.4mg的芳香胺，9.2mg的Pd(acac)2，15.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物119mg，产率93％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.12–7.04(m,4H),6.95–6.86(m,4H),5.36(bs,1H),3.83(s,3H),2.33(s,3H)；13C NMR(100MHz,CDCl3)δ154.8,142.5,136.7,129.9,129.3,121.1,116.6,114.7,55.6,20.6.
实施例2
Figure BDA0002071715990000062
在氮气氛围中，往干燥的封管中加入120mg的上述硝基芳烃，96.4mg的芳香胺，1.4mg的Pd(OAc)2，30.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的甲苯，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物125.9mg，产率80％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.40–7.30(m,4H),7.29–7.20(m,2H),7.17–7.10(m,2H),6.98(d,J＝8.2Hz,2H),6.93–6.83(m,3H),5.27(bs,1H),2.20(s,3H)；13C NMR(100MHz,CDCl3)δ140.9,140.5,139.1,131.2,130.9,129.9,129.4,129.0,128.3,127.5,120.5,119.4,116.6,20.8.
实施例3
Figure BDA0002071715990000071
在氮气氛围中，往干燥的封管中加入92mg的上述硝基芳烃，96.4mg的芳香胺，10.6mg的PdCl2，45.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的甲苯，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产38.2mg，产率30％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.15-7.13(m,1H),7.04–6.96(m,4H),6.81–6.69(m,3H),6.01(bs,1H),3.79(s,3H),2.22(s,3H)；13C NMR(100MHz,CDCl3)δ148.0,139.9,133.7,131.2,129.8,120.9,119.7,119.4,113.9,110.4,55.6,20.8.
实施例4
Figure BDA0002071715990000072
在氮气氛围中，往干燥的封管中加入100.9mg的上述硝基芳烃，96.4mg的芳香胺，9.7mg的Pd(TFA)2，60.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物54.9mg，产率40％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ9.46(s,1H),8.19(dd,J＝8.6,1.5Hz,1H),7.34(m,1H),7.23(d,J＝8.1Hz,2H),7.19–7.12(m,3H),6.73(m,1H),2.39(s,3H)；13C NMR(100MHz,CDCl3)δ143.7,135.9,135.7,135.7,132.8,130.3,126.6,124.8,117.1,116.0,21.0.
实施例5
Figure BDA0002071715990000081
在氮气氛围中，往干燥的封管中加入120mg的上述硝基芳烃，96.4mg的芳香胺，11.20mg的烯丙基氯化钯，30.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的正己烷，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物129.6mg，产率80％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.61(d,J＝7.2Hz,2H),7.46(t,J＝7.5Hz,2H),7.41–7.31(m,2H),7.29(t,J＝1.9Hz,1H),7.19–7.01(m,6H),5.65(bs,1H),2.36(s,3H)；13C NMR(100MHz,CDCl3)δ144.3,142.6,141.3,140.1,131.4,130.0,129.8,128.7,127.4,127.2,119.5,119.3,115.9,115.7,20.8.
实施例6
Figure BDA0002071715990000082
在氮气氛围中，往干燥的封管中加入108.7mg的上述硝基芳烃，96.4mg的芳香胺，7.8mg的PdCl2(MeCN)2，30.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的正己烷，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物108.9mg，产率75％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.66(s,1H),7.53(d,J＝7.6Hz,1H),7.29(t,J＝7.9Hz,1H),7.18(dd,J＝7.7,1.9Hz,1H),7.07(dd,J＝38.0,8.2Hz,4H),5.16(s,1H),3.89(s,3H),2.33(s,3H)；13C NMR(100MHz,CDCl3)δ167.2,144.3,139.5,131.8,131.3,130.0,129.3,121.2,120.6,119.5,117.3,52.1,20.8.
实施例7
Figure BDA0002071715990000091
在氮气氛围中，往干燥的封管中加入120mg的上述硝基芳烃，96.4mg的芳香胺，9.2mg的Pd(acac)2，30.0mg的咪唑盐L3，240mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物124.7mg，产率80％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.70–7.65(m,2H),7.62–7.56(m,2H),7.55–7.48(m,2H),7.43–7.36(m,1H),7.21(d,J＝8.1Hz,2H),7.19–7.11(m,4H),5.54(bs,1H),2.43(s,3H)；13CNMR(100MHz,CDCl3)δ143.4,141.0,140.1,133.2,131.3,130.1,128.9,128.1,126.6，126.6,119.3,117.1,20.9.
实施例8
Figure BDA0002071715990000101
在氮气氛围中，往干燥的封管中加入mg的上述硝基芳烃，96.4mg的芳香胺，9.2mg的Pd(acac)2，30.0mg的咪唑盐L3，320mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，160℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物72.6mg，产率60％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.11(d,J＝8.4Hz,2H),7.03-6.94(m,6H),5.18(bs,1H),2.34(s,3H)；13C NMR(100MHz,CDCl3)δ157.7(d,J＝239.0Hz,0H),141.1(s,3H),139.8(d,J＝2.4Hz,3H),130.6(s,3H),130.0(s,13H),119.5(d,J＝7.7Hz,13H),118.0(s,13H),115.9(d,J＝22.2Hz,13H),20.7(s,5H)；19F NMR(376MHz,CDCl3)δ-122.9.
实施例9
Figure BDA0002071715990000102
在氮气氛围中，往干燥的封管中加入99.1mg的上述硝基芳烃，96.4mg的芳香胺，1.8mg的Pd(acac)2，30.0mg的咪唑盐L3，254mg的磷酸三钾，3mL的二氧六环，然后拧紧封管螺纹帽，100℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物27.2mg，产率20％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.84(d,J＝8.8Hz,2H),7.16(d,J＝8.2Hz,2H),7.09(d,J＝8.4Hz,2H),6.94(s,1H),6.92(s,1H),5.62(bs,1H),2.52(s,3H),2.34(s,3H)；13C NMR(100MHz,CDCl3)δ196.5,149.1,137.8,133.4,130.7,130.1,128.5,121.6,113.9,26.1,20.9.
实施例10
Figure BDA0002071715990000111
在氮气氛围中，往干燥的封管中加入104.5mg的上述硝基芳烃，96.4mg的芳香胺，18.4mg的Pd(acac)2，30.0mg的咪唑盐L3，273mg的氟化铯，3mL的二氧六环，然后拧紧封管螺纹帽，100℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物84.2mg，产率60％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ9.22(s,1H),8.48(d,J＝6.0Hz,1H),7.77(d,J＝6.0Hz,1H),7.54(d,J＝7.4Hz,1H),7.48–7.39(m,2H),7.12(d,J＝8.1Hz,2H),7.00(d,J＝8.3Hz,2H),6.20(s,1H),2.33(s,3H)；13C NMR(100MHz,CDCl3)δ152.9,142.5,140.5,139.4,131.6,130.1,129.2,129.0,127.7,120.4,119.5,116.0,114.7,20.8.
实施例11
Figure BDA0002071715990000112
在氮气氛围中，往干燥的封管中加入74.5mg的上述硝基芳烃，96.4mg的芳香胺，9.2mg的Pd(acac)2，30.0mg的咪唑盐L3，137mg的碳酸铯，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应48h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物44.2mg，产率40％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ8.33(d,J＝2.2Hz,1H),8.08(d,J＝4.2Hz,1H),7.35(d,J＝9.7Hz,1H),7.15–7.05(m,3H),7.01(d,J＝8.4Hz,2H),6.32(bs,1H),2.31(s,3H)；13C NMR(100MHz,CDCl3)δ141.0,140.5,139.2,138.9,131.9,130.1,123.9,122.4,119.4,20.8.
实施例12
Figure BDA0002071715990000121
在氮气氛围中，往干燥的封管中加入103.9mg的上述硝基芳烃，194.7mg的芳香胺，9.2mg的Pd(acac)2，30.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物138.1mg，产率80％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ8.22–8.16(m,1H),8.02–7.96(m,1H),7.68–7.60(m,2H),7.42(d,J＝8.1Hz,1H),7.35(t,J＝7.8Hz,1H),7.20(s,2H),6.39(dd,J＝7.5,1.0Hz,1H),5.69(bs,1H),2.86–2.59(m,4H),2.55(s,3H),1.30(t,J＝7.6Hz,6H)；13C NMR(100MHz,CDCl3)δ142.8,141.9,136.1,134.8,134.7,129.0,127.7,126.8,125.9,125.1,123.7,120.3,118.3,106.9,24.7,21.4,15.1.
实施例13
Figure BDA0002071715990000122
在氮气氛围中，往干燥的封管中加入103.9mg的上述硝基芳烃，111.1mg的芳香胺，9.2mg的Pd(acac)2，30.0mg的咪唑盐L5，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应12h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物163.0mg，产率87％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,DMSO)δ9.49(s,1H),8.03–7.96(m,2H),7.85(d,J＝7.7Hz,1H),7.78(d,J＝8.7Hz,1H),7.60–7.51(m,4H),7.31(d,J＝2.2Hz,1H),7.00(dd,J＝8.7,2.2Hz,1H)；13C NMR(100MHz,DMSO)δ150.8,136.7,135.0,134.4,132.26(q,J＝31.3Hz),128.6,128.4,126.6,126.4,126.0(d,J＝13.4Hz),124.0,122.5,121.3,121.1,116.8,115.5,111.7,94.3；19F NMR(376MHz,DMSO)δ-61.58.
实施例14
Figure BDA0002071715990000131
在氮气氛围中，往干燥的封管中加入103.9mg的上述硝基芳烃，128.5mg的芳香胺，9.2mg的Pd(acac)2，30.0mg的咪唑盐L4，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应36h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物135.7mg，产率97％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.97(d,J＝8.1Hz,1H),7.90(d,J＝8.4Hz,1H),7.65–7.41(m,9H),6.77(d,J＝7.4Hz,1H),4.85(bs,1H),4.59(s,2H)；13C NMR(100MHz,CDCl3)δ143.4,139.3,134.5,128.9,127.9,127.6,126.8,126.0,125.0,123.6,120.2,117.9,105.1,48.7.
实施例15
Figure BDA0002071715990000141
在氮气氛围中，往干燥的封管中加入103.9mg的上述硝基芳烃，78.0mg的吗啡啉，9.2mg的Pd(acac)2，30.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应48h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物108.2mg，产率84％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ8.25(dd,J＝8.1,1.6Hz,1H),7.89–7.84(m,1H),7.60(d,J＝8.2Hz,1H),7.55–7.47(m,2H),7.44(t,J＝7.6Hz,1H),7.11(dd,J＝7.4,0.9Hz,1H),4.01(t,J＝4.4Hz,4H),3.14(t,J＝4.4Hz,4H)；13C NMR(100MHz,CDCl3)δ149.5,134.8,128.8,128.5,126.0,125.9,125.5,123.9,123.5,114.7,67.5,53.5.
实施例16
Figure BDA0002071715990000142
在氮气氛围中，往干燥的封管中加入103.9mg的上述硝基芳烃，90.1mg的N-胺基哌啶，9.2mg的Pd(acac)2，20.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物117.5mg，产率86％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.88–7.82(m,2H),7.51–7.40(m,3H),7.39–7.30(m,2H),5.06(s,1H),2.81(s,4H),1.83–1.75(m,4H),1.52(s,2H)；13C NMR(100MHz,CDCl3)δ142.2,134.4,128.7,126.8,125.6,124.7,122.9,120.1,119.0,107.7,57.4,26.2,23.8.
实施例17
Figure BDA0002071715990000151
在氮气氛围中，往干燥的封管中加入103.9mg的上述硝基芳烃，96.4mg的N-甲基芳香胺，9.2mg的Pd(acac)2，15.0mg的咪唑盐L2，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物99.7mg，产率71％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ8.03(d,J＝8.4Hz,2H),7.91(d,J＝8.2Hz,1H),7.62(t,J＝7.8Hz,2H),7.55(t,J＝7.6Hz,1H),7.50(d,J＝7.3Hz,1H),7.29(t,J＝7.5Hz,2H),6.87(t,J＝6.8Hz,1H),6.76(d,J＝8.4Hz,2H),3.52(s,3H)；13C NMR(100MHz,CDCl3)δ150.2,145.5,135.3,131.5,129.1,128.6,126.8,126.6,126.5,126.4,125.4,124.0,117.4,113.7,40.3.
实施例18
Figure BDA0002071715990000152
在氮气氛围中，往干燥的封管中加入103.9mg的上述硝基芳烃，43.9mg的正丁胺，9.2mg的Pd(acac)2，20.0mg的咪唑盐L3，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物110.6mg，产率92％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ7.85(dd,J＝7.0,2.5Hz,2H),7.54–7.45(m,2H),7.42(t,J＝7.9Hz,1H),7.29(d,J＝8.2Hz,1H),6.68(d,J＝7.5Hz,1H),4.41(bs,1H),3.32(t,J＝7.1Hz,2H),1.80(dt,J＝14.6,7.3Hz,2H),1.57(dq,J＝14.6,7.3Hz,2H),1.06(t,J＝7.4Hz,3H)；13C NMR(100MHz,CDCl3)δ143.6,134.4,128.7,126.7,125.7,124.7,123.4,119.9,117.3,104.5,44.1,31.6,20.6,14.1.
实施例19
Figure BDA0002071715990000161
在氮气氛围中，往干燥的封管中加入103.9mg的上述硝基芳烃，171.8mg的5-氨基喹啉，9.2mg的Pd(acac)2，15.0mg的咪唑盐L1，480mg的磷酸三钾三水合物，3mL的二氧六环，然后拧紧封管螺纹帽，130℃下反应24h。反应结束后用硅藻土过滤，浓缩，过硅胶柱，得到产物141.8mg，产率87％。
对本实施例制备得到的产物进行核磁共振分析：
1H NMR(400MHz,CDCl3)δ8.92(dd,J＝4.2,1.6Hz,1H),8.40–8.35(m,1H),8.07(d,J＝8.4Hz,1H),7.90(d,J＝7.6Hz,1H),7.82(d,J＝8.5Hz,1H),7.59–7.45(m,4H),7.36–7.29(m,2H),7.02(d,J＝7.5Hz,1H),6.95(d,J＝7.4Hz,1H),6.44(s,1H)；13C NMR(100MHz,CDCl3)δ150.5,149.3,140.6,140.1,134.7,130.8,129.9,128.7,126.9,126.3,126.2,125.9,123.7,122.9,122.2,121.8,120.4,116.0,115.8.

Claims (9)

1.一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法，其特征在于，包括：在有机溶剂中，以钯/咪唑盐为催化剂，将硝基芳烃和胺类化合物在碱的作用下进行偶联反应，经后处理得到芳香族化合物；
所述的硝基芳烃的结构如下式(I)所示：
Ar-NO2 (I)
所述的胺类化合物的结构如下式(II)所示：
Figure FDA0003314895080000011
式(I)中，Ar为芳基或杂芳基；式(II)中，R1为氢或烷基，R2为烷基、芳基或杂芳基；
所述的咪唑盐的结构如下式(III)所示：
Figure FDA0003314895080000012
式(III)中，R1、R2、R3独立的选自氢、卤素、烷基或烷氧基，Y-为Cl-、Br-、I-、PF6 -或PF4 -。
2.根据权利要求1所述的合成芳香胺化合物的方法，其特征在于，式(I)中，Ar为苯基、取代苯基或含氮杂芳基，所述的取代苯基为式(IV)所示结构式中的任意一种：
Figure FDA0003314895080000021
式(IV)中，*表示–NO2的连接位置；
式(II)中，R1为氢或烷基，R2为烷基、苯基、取代苯基或含氮杂环，所述的取代苯基为式(V)所示结构式中的任意一种：
Figure FDA0003314895080000022
式(V)中，*表示R1–NH–的连接位置。
3.根据权利要求1所述的合成芳香胺化合物的方法，其特征在于，所述的咪唑盐的结构如下式L1～L9所示：
Figure FDA0003314895080000023
4.根据权利要求1所述的合成芳香胺化合物的方法，其特征在于，所述的钯为乙酰丙酮钯(II)、醋酸钯(II)、氯化钯(II)、双(乙腈)氯化钯(II)、双(三苯基膦)氯化钯(II)、三氟乙酸钯(II)、三(二亚苄基丙酮)二钯或烯丙基氯化钯(II)二聚体中的任意一种。
5.根据权利要求1所述的合成芳香胺化合物的方法，其特征在于，所述的有机溶剂为二氧六环、甲苯、四氢呋喃、N,N-二甲基甲酰胺、乙腈、甲基叔丁基醚、正庚烷、异丙醇或乙二醇二甲醚中的任意一种。
6.根据权利要求1所述的合成芳香胺化合物的方法，其特征在于，所述的碱为磷酸三钾三水合物、无水磷酸钾、碳酸钾、氟化铯、碳酸铯、乙酸钾、磷酸氢二钾、氢氧化钾、三乙胺或1,8-二氮杂二环十一碳-7-烯中的任意一种。
7.根据权利要求1所述的合成芳香胺化合物的方法，其特征在于，所述的偶联反应的温度为100～160℃，反应时间为12～48h。
8.根据权利要求1所述的合成芳香族化合物的方法，其特征在于，所述的钯、咪唑盐和硝基芳烃的摩尔比为1：(1～4)：(5～100)。
9.根据权利要求1所述的合成芳香族化合物的方法，其特征在于，所述的硝基芳烃、胺类化合物和碱的摩尔比为1：(1～3)：(1～5)。
CN201910439860.8A 2019-05-24 2019-05-24 一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法 Active CN110105230B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910439860.8A CN110105230B (zh) 2019-05-24 2019-05-24 一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910439860.8A CN110105230B (zh) 2019-05-24 2019-05-24 一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法

Publications (2)

Publication Number Publication Date
CN110105230A CN110105230A (zh) 2019-08-09
CN110105230B true CN110105230B (zh) 2022-03-01

Family

ID=67492184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910439860.8A Active CN110105230B (zh) 2019-05-24 2019-05-24 一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法

Country Status (1)

Country Link
CN (1) CN110105230B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003263B (zh) * 2023-01-06 2024-06-21 中山大学 一种有机膦催化硝基芳烃、硝基烷烃与格式试剂还原偶联制备芳胺类化合物的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770414A (zh) * 2010-04-28 2012-11-07 第一三共株式会社 ［5,6］杂环化合物
US20140248646A1 (en) * 2013-03-04 2014-09-04 Indiana University Research And Technology Corporation IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6794041B2 (ja) * 2016-10-31 2020-12-02 東ソー株式会社 芳香族アミンの製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770414A (zh) * 2010-04-28 2012-11-07 第一三共株式会社 ［5,6］杂环化合物
US20140248646A1 (en) * 2013-03-04 2014-09-04 Indiana University Research And Technology Corporation IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Buchwald–Hartwig Amination of Nitroarenes;Fumiyoshi Inoue等;《Angew. Chem. Int. Ed.》;20170922;第56卷;第13307–13309页 *
Expanding Pd-Catalyzed C-N Bond-Forming Processes: The First Amidation of Aryl Sulfonates, Aqueous Amination, and Complementarity with Cu-Catalyzed Reactions;Xiaohua Huang等;《J. AM. CHEM. SOC.》;20030705;第125卷;第6653-6655页 *

Also Published As

Publication number Publication date
CN110105230A (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
Wang et al. pH-Responsive N-heterocyclic carbene copper (I) complexes: syntheses and recoverable applications in the carboxylation of arylboronic esters and benzoxazole with carbon dioxide
CN112221540B (zh) Pd2+负载的金属有机框架复合催化剂及制备方法与应用
WO2013159229A1 (en) Silanyloxyaryl phosphine ligand and uses thereof in c-n cross-coupling
CN113563370A (zh) 一种壳聚糖负载铜材料催化制备α位有取代基的β-硼基酮的制备方法
CN112876516A (zh) N-(4-吲哚基)氮杂环卡宾钯络合物及应用
CN109694382B (zh) 一种室温下制备芳基硼酸酯的方法
CN110105230B (zh) 一种钯/咪唑盐催化硝基芳烃和胺类化合物合成芳香胺化合物的方法
Fortea-Pérez et al. Structurally characterized dipalladium (ii)-oxamate metallacyclophanes as efficient catalysts for sustainable Heck and Suzuki reactions in ionic liquids
CN102500418B (zh) 磁性双齿亚胺钯配体催化剂的制备方法
CN113817174A (zh) 原位酰肼三维MOFs材料的制备方法及其用途
CN111744551A (zh) 锂配合物在腈的硼氢化反应中的应用
CN110105179B (zh) 一种钯/咪唑盐催化硝基芳烃和硼酸化合物偶联合成芳香族化合物的方法
CN109593085B (zh) 吡啶-酰胺-噁唑啉配体、其合成方法及其金属配合物和用途
CN109810147B (zh) 芘标记的苯并咪唑氮杂环卡宾钯金属配合物及制备和应用
Panahi et al. Rhodium‐Catalyzed Asymmetric Macrocyclization towards Crown Ethers Using Hydroamination of Bis (allenes)
CN103748065A (zh) 2－烯基胺化合物的制造方法
CN108948055B (zh) 一种8-甲基喹啉偕二硼化合物及其制备方法
CN108658802B (zh) 一种手性双[n,o]环钯配合物及其合成方法
CN111039767B (zh) 一种三唑卡宾催化制备氘代醛的方法
CN114849787B (zh) 一种芳基双齿膦配体聚合物原位封装铑基催化材料及其制备方法和应用
CN112694489A (zh) N-杂环卡宾铜催化剂的制备方法
CN109021002B (zh) 一种萘-1,8-二胺基芳基硼酰胺的制备方法
CN111545247B (zh) 一种sba-15负载的多相手性膦金催化剂及其制备方法和应用
US9340519B2 (en) Paracyclophane-based ligands, their preparation and use in catalysis
CN113372255B (zh) 一种铜催化合成2-取代吲哚衍生物的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant